Chandan Healthcare has reached an amicable settlement with Dayal Institute of Medical Sciences Limited, leading to the complete withdrawal of a complaint alleging financial irregularities. The resolution removes regulatory uncertainty for the healthcare diagnostics firm, which had faced scrutiny from multiple statutory authorities including the Securities and Exchange Board of India (SEBI) and the National Stock Exchange (NSE). The settlement was confirmed via communication dated July 31, 2026, following the reconciliation and balance confirmation of accounts between the parties.

The original complaint was filed on May 18, 2026, by Dayal Institute of Medical Sciences Limited, formerly known as Chandan Institute of Medical Sciences Limited. The complainant, represented by Managing Director Rajesh Singh Dayal, had lodged grievances with the Office of the Registrar of Companies, Uttar Pradesh, concerning alleged financial irregularities in the affairs of Chandan Healthcare Limited and other entities within the Chandan Group. The complaint was subsequently forwarded to various statutory and regulatory authorities.

Settlement Details

Following negotiations and account reconciliations, both parties agreed to settle all disputes, differences, and claims arising from the matter. Dayal Institute of Medical Sciences Limited requested that concerned authorities treat the matter as closed. The withdrawal covers all allegations against Chandan Healthcare Limited, its promoters, directors, officers, group companies, and connected entities.

Chandan Healthcare Limited disclosed the development under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company stated that the withdrawal of the complaint and the settlement of the matter remove the uncertainty arising from the earlier allegations. Management believes this resolution will have no adverse impact on the operations or financial position of the company.

Regulatory Notifications

Copies of the withdrawal communication were sent to multiple regulatory bodies to ensure the closure of proceedings across all forums. These notifications were addressed to:

• The Manager, Listing Department, National Stock Exchange of India Limited
• The Inspector General / Head of Department, Economic Offences Wing, Uttar Pradesh Police
• The Regional Director, Northern Region-1, Ministry of Corporate Affairs
• The Registrar of Companies, Uttar Pradesh-I at Kanpur

The disclosure was signed by Rajeev Kumar Nain, Company Secretary & Compliance Officer of Chandan Healthcare Limited. The company’s registered office is located in Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow.

Chandan Healthcare Limited held a virtual analysts' and investors' meeting on June 30, 2026, to engage with key market stakeholders. The session was conducted under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The interaction followed a question-and-answer format, and no presentation was made by the company officials during the event. No Unpublished Price Sensitive Information (UPSI) was shared or discussed during the meeting.

The meeting saw participation from 32 attendees, including representatives from various financial institutions and High Net-Worth Individuals (HNIs). The participants engaged with the company management through a webinar format during the scheduled time slot from 02:35 PM to 03:30 PM IST.

Attendee Details

The following table details the organizations and investor names that participated in the meeting: